Browse by Series:

FDA Approval in Bladder Cancer, Breakthrough Therapy Designation in DLBCL, and More

George R. Simon, MD
Published: Friday, Apr 21, 2017



George R. Simon, MD, reports on an FDA approval in bladder cancer, a breakthrough therapy designation in diffuse large B-cell lymphoma, an ODAC hearing scheduled for a drug in HER2-positive breast cancer, an FDA elimination for REMS certification prior to select treatments, and 2 disappointing phase III results in non–small cell lung cancer and triple-negative breast cancer.
SELECTED
LANGUAGE
Slider Left
Slider Right


George R. Simon, MD, reports on an FDA approval in bladder cancer, a breakthrough therapy designation in diffuse large B-cell lymphoma, an ODAC hearing scheduled for a drug in HER2-positive breast cancer, an FDA elimination for REMS certification prior to select treatments, and 2 disappointing phase III results in non–small cell lung cancer and triple-negative breast cancer.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x